| Sep 15 |
Ten-Year Data for Merck’s KEYTRUDA® (pembrolizumab) Demonstrates Sustained Overall Survival Benefit Versus Ipilimumab in Advanced Melanoma
|
| Sep 14 |
J&J leads H1 healthcare deals as Big Pharma dealmaking returns: report
|
| Sep 14 |
Merck Keytruda with Eisai’s Lenvima succeeds in late-stage trial for liver cancer
|
| Sep 14 |
Is Merck & Co. (MRK) the Best Blue Chip Stock To Invest In According to Short Sellers?
|
| Sep 14 |
Merck Keytruda cuts mortality risk by 33% in late-stage trial for cervical cancer
|
| Sep 14 |
Merck & Co., Inc. (MRK): A Good Beginner Stock According to Analysts
|
| Sep 14 |
KEYTRUDA® (pembrolizumab) Plus LENVIMA® (lenvatinib) in Combination With Transarterial Chemoembolization Significantly Improved Progression-Free Survival Compared to TACE Alone in Patients With Unresectable, Non-Metastatic Hepatocellular Carcinoma
|
| Sep 14 |
Merck’s KEYTRUDA® (pembrolizumab) Plus Chemoradiotherapy (CRT) Reduced Risk of Death by 33% Versus CRT Alone in Patients With Newly Diagnosed High-Risk Locally Advanced Cervical Cancer
|
| Sep 14 |
TIGIT drug from iTeos shrinks lung tumors in trial
|
| Sep 14 |
Merck Keytruda cuts mortality risk in gastric cancer by 20%
|
